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resistant prostate cancer treated with docetaxel chemotherapySince 2004, docetaxel chemotherapy has been reported to be
effective and relatively safe in metastatic prostate cancer patients
after failure with androgen deprivation therapy.1,2 Not only pro-
longing survival, docetaxel chemotherapy has also beneﬁts of relief
of bony pain and improved quality of life. Using a standard 3-
weekly docetaxel regimen (75 mg/m2), in the arm, 45% of patients
had signiﬁcant serum prostate-speciﬁc antigen (PSA) response
(>50% reduction) with a median duration of 7.7 months; by
contrast, patients using a 3-weekly mitoxantrone regimen, in the
arm, had a 32% PSA responsewith amedian duration of 7.8months.1
Similarly, Kellokumpu-Lehtinen et al,3 reported in the Lancet
Oncology that a 2-weekly docetaxel regimen (50 mg/m2) had 49%
PSA response while a standard 3-weekly docetaxel regimen had
42% PSA response. Moreover, docetaxel chemotherapy can also pro-
long the patients' overall survival in high-volume hormone-sensi-
tive metastatic prostate cancer.4 Despite these promising data,
there is a lack of ideal markers predicting for disease-speciﬁc sur-
vival or overall survival.
Currently, there is no clear consensus regarding the optimum
duration or response predictors of chemotherapy for metastatic
castrate-resistant prostate cancer (mCRPC) patients. Despite this,
several small cohorts explored the prognostic signiﬁcance of PSA-
related parameters in mCRPC patients. Thomas et al5 reported in
a cohort of 41 consecutive mCRPC patients treated with 3-weekly
docetaxel chemotherapy that time to PSA nadir of <16 weeks is
an independent unfavorable predictor for response duration and
progression-free survival. These ﬁndings were consistent with
those in the articles by professor Huang's group.6,7 Interestingly,
Huang et al7 reported in a large cohort of 650 patients with
advanced or metastatic prostate cancer treated with androgen
deprivation therapy (ADT) that the time to PSA nadir is an indepen-
dent prognostic predictor for disease progression. Although the real
mechanism is unclear, the author thought it may reﬂect a compli-
cated role of androgeneandrogen receptor axis in prostate cancer.
Indeed, recent studies also demonstrated that the development of
lethal prostate cancer is also a dynamics process that follows the
Darwinian evolutionary rule.8,9 Despite these conceptual pro-
gresses, it is important to know how to use these predictors in
practice.
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